去纤维钠是什么药？治什么？

What is defibrotide sodium? What to treat? Defibrotide is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects. In recent years, multiple clinical research results have shown that Defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT. Defibrotide is indicated for the treatment of adults and children with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). Defibrotide also has a certain therapeutic effect on multiple myeloma. It has achieved good results in the treatment of multiple myeloma and hepatic veno-occlusive disease caused by chemotherapy and stem cell transplantation, meeting the treatment needs of this rare and fatal disease.

The recommended dose of Defibrotide for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Defibrotide was administered for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue Defibrotide until resolution of VOD or up to a maximum of 60 days.

Defibrotide must be diluted before infusion. Prior to administration of Defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Defibrotide is administered by constant intravenous infusion over a 2-hour period. Administer the diluted defibrotide solution using an infusion set equipped with a 0.2 μm in-line filter. Flush the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration. Do not coadminister Defibrotide with other intravenous medications at the same time and in the same intravenous line. 

Receiving Defibrotide treatment will also produce certain side effects or adverse reactions. The most common side effects of this drug include: hypotension/diarrhea/vomiting/nausea/nose bleeding, etc. The incidence rate of grade 3-4 reactions related to defibrotide is 7%, mainly hypotension/pulmonary and gastrointestinal bleeding/abdominal cramps, etc. The side effects of Defibrotide are usually mild, and patients do not need to worry too much.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: